Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bortezomib + dexamethasone + zoledronic acid on bone outcomes in relapsed multiple myeloma
2007-005953-49Phase 2Completed
- Sponsor
- Prof. M.A. Dimopoulos
- Start
- Oct 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, dexamethasone and zoledronic acid in multiple myeloma (MM), sponsored by Prof. M.A. Dimopoulos. Primary endpoint: Bone mineral density following 4 cycles of treatment or at termination of combination therapy. Started Oct 2009; status: completed.
02
Drugs
bortezomibdexamethasonezoledronic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2007-005953-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005953-49.